Keppra injection is an alternative for patients when oral administration is temporarily not feasible. It must be diluted prior to use and administered as a 15-minute intravenous infusion.
“This US approval closely follows the European approval of the IV formulation for Keppra earlier this year. Keppra is now the only newer anti-epileptic drug available in the US and Europe with both oral and intravenous formulations,” said Troy Cox, president of CNS operations at UCB.
In March 2006, the European Commission approved the use of Keppra 100mg/mL concentrate for solution for intravenous infusion for use as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adults and children four years of age and older with epilepsy.